Revance Therapeutics, Inc. (RVNC) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $0.80 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 25%. A quarter ago, it was expected that this company would post a loss of $0.66 per share when it actually produced a loss of $0.54, delivering a surprise of 18.18%. Over the last four quarters, the company ha ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ Commission File No. 001-36297 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 77-0551645 (State or other ...

Exhibit 99.1 REVANCE Revance Reports Second Quarter 2024 Financial Results, Provides Corporate Update – Q2 total DAXXIFY® and RHA® (by Teoxane SA) product revenue of $65.3 million, a YoY increase of 20%. – Q2 DAXXIFY net revenue of $28.7 million, a YoY increase of 27%. – Q2 DAXXIFY aesthetic units sold increased 65% YoY and 15% QoQ; over 3,700 ordering accounts reached. – Q2 RHA Collection net revenue of $36.6 million, a YoY increase of 15%. – Revance launched DAXXIFY for cervical dystonia, with coverage wi ...

A downtrend has been apparent in Revance Therapeutics, Inc. (RVNC) lately with too much selling pressure. The stock has declined 18.9% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround. Here is How to Spot Oversold Stocks We use Relative Strength Index (RSI), one of the most commonly used technical in ...

Company Participants Operator Thank you, operator. Joining us on the call today from Revance are President and Chief Executive Officer, Mark Foley, and Chief Financial Officer, Toby Schilke. With that, I will turn the call over to Mark Foley, President and Chief Executive Officer of Revance. Mark? Specifically, DAXXIFY aesthetic units sold were up 105% year-over-year and notably up 7% on a quarter-overquarter basis, despite Q1 traditionally being a seasonally down quarter when compared to Q4. Moreover, DAXX ...

I would now like to turn the conference call over to Jessica Serra, Head of Investor Relations, Corporate Communications and ESG for Revance. Please go ahead. Jessica Serra Mark Foley Mark Foley 2023 was an important year for Revance. We realized several pivotal milestones, including the launch of DAXXIFY and aesthetics and the FDA approval of DAXXIFY for cervical dystonia in addition to achieving record product revenue of $213 million, up 80% year-over-year. From a balance sheet perspective, we ended the y ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ Commission File No. 001-36297 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 77-0551645 State or other juris ...

Revenue for the third quarter included $54.1 million of product revenue and $2.7 million of service revenue. Turning to OpEx, in connection with our planned exit of the OPUL payments business by the end of Q1 2024, we recorded restructuring charges of $95.2 million as of September 30, 2023, and expect to record an additional $3 million in charges through the three months ending March 31, 2024. GAAP OpEx for the third quarter was $196.1 million, compared to $106.5 million for the same period in 2022. Excludi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ For the transition period from ___ to ___ Commission File No. 001-36297 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 77-0551645 (State or o ...

Revance Therapeutics, Inc. (NASDAQ:RVNC) Q2 2023 Earnings Conference Call August 8, 2023 4:30 PM ET Company Participants Welcome to the Revance Therapeutics Second Quarter 2023 Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode. Following managementÂ's prepared remarks, we will hold a Q&A session. [Operator Instructions]. As a reminder, this call is being recorded today, Tuesday, August 8, 2023. I would now like to turn the conference call over t ...